Puridify and GSK extend evaluation of FibroSelect purification technology

Developers of bioprocessing purification technologies, Puridify, has announced an 18-month collaboration with pharma company GlaxoSmithKline.

The agreement has been signed to extend the evaluation of Puridify’s FirbroSelect purification technology. Furthermore, the two companies are aiming towards building a package to support potential use of nanofibers in toxicology and clinical manufacture.

Puridify and GlaxoSmithKline previously completed an 18-month collaboration which saw the successful demonstration of proof of concept studies with potential economic benefits based on the technology’s use.

Puridify are aiming to deliver industry-ready technology that will give the life sciences industry a change to current downstream processing of industrial biotherapeutic manufacture.

Dr. Oliver Hardick, chief executive officer of Puridify said: “The development of FibroSelect has focused on generating industry relevant end-user data.  At the same time, we have been establishing a manufacturing basis for GMP-compliant products that are delivered pre-packed and ready-to-operate.”

“Our single-use purification units will enable this technology to service very effectively the wider Life Sciences industry. Specifically, collaborations with biotherapeutic drug manufacturers are already proving the benefit of FibroSelect as a single-use high productivity product capture platform, suitable for existing and emergent biologic therapies.”

“We are delighted that GSK are continuing to support us in such a significant manner, particularly as we approach commercial manufacture of the FibroSelect technology. This kind of industrial collaboration is critical for shaping the technology and generating data to support its market adoption.”